Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Cytyc to sell bonds to pay for Novacept:

This article was originally published in Clinica

Executive Summary

Cervical cancer screening group Cytyc plans to sell $220m of convertible notes to help fund its $311m net cash purchase of Novacept. The Boxborough, Massachusetts-based company plans to sell the notes to qualified institutional buyers, and to grant the initial purchasers an option to buy up to $30m in additional notes. Cytyc announced its intention to acquire Novacept, which makes the NovaSure device to treat menorrhagia, earlier this month (see Clinica No 1098, p 13). It had said it would fund the deal through cash in hand and a bank financing.






Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts